The article New Study: Microdosing Related to Lower Anxiety and Depression was originally published on Microdose.
From Silicon Valley tech execs looking to enhance performance, to common folk hoping to improve mental health, adding a microdose of psychedelics to your routine is growing in popularity.
The anecdotal evidence has always been there. People swear the practice has improved their lives. But up to now there has been a lack of scientific data to support people’s subjective claims (there was even a small yet respectable study that showed microdosing benefits could be partially from placebo-effect).
However this week we received some encouraging scientific news that supports people’s claims. Published on Nature.com (Scientific Reports) we have a report whose title speak for itself:
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
The report — although performed without placebo control — had a huge sample size, the largest of its kind. And it was run by a group of respected scientists and academics, including the Mushroom Man himself, Paul Stamets.
Some highlights from the study (information taken directly from the report):
- The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers (n = 4050) and non-microdosers (n = 4653) via a mobile application.
- Psilocybin was the most commonly used microdose substances in our sample (85%) and we identified diverse microdose practices with regard to dosage, frequency, and the practice of stacking which involves combining psilocybin with non-psychedelic substances such as Lion’s Mane mushrooms, chocolate, and niacin.
- Microdosers were generally similar to non-microdosing controls with regard to demographics, but were more likely to report a history of mental health concerns. Among individuals reporting mental health concerns, microdosers exhibited lower levels of depression, anxiety, and stress across gender.
- This examination of a large international sample of adults highlights the prominence of therapeutic and wellness motivations for microdosing psychedelic drugs and identified lower levels of anxiety and depression among microdosers relative to controls.
Encouraging news that will surely give researchers more institutional support to continue with more rigorous studies on the benefits of microdosing.
Interested in more coverage of psychedelic research? Check out New Yale Study Shows Psilocybin Spurs Growth of Neural Connections Lost in Depression and Another Study Shows Psilocybin Effective Against Depressionpsilocybin mushroom psychedelic psychedelic research microdosing depression anxiety research psychedelics
Getting Ahead of the Psychedelics Supply Crunch
UK’s medical pot industry could reach £1.2B through reform: report
Cybin Gets FDA Approval For New Phase 2 Trial
CBD, ‘Snake Oil’ or Life-Changing?
New Study Shows Mushrooms Can Reverse Alcohol Brain Damage
Compass Phase 2 Study Shows Positive Results For TRD
Cell wall remodeling enables fungal network development in grasses
Are Reopening Penny Stocks Worth Buying After the Market Crash?
BigID Announces Auto-Discovery Apps For Cloud At AWS Re:Invent
Common antidepressant escitalopram and psilocybin can be taken together safely: study
Public Companies10 hours ago
Bright Minds Bioscience: A Deep Dive
Psilocybin13 hours ago
Magic Mushrooms for Mental Health: A Look at Anxiety, Depression, and Bi-Polar Disorder
Psilocybin11 hours ago
Florida Lawmaker Files Bill to Decriminalize All Drugs
Markets & Investing8 hours ago
Microdose Psychedelic Capital: Ethics in Psychedelics
Psychedelics8 hours ago
Psychedelic Titans with Larry Zeifman of Zeifmans LLP
Psilocybin15 hours ago
AREV Life Sciences / Absolem JV Receives Extraction Results
Markets & Investing12 hours ago
Delta-8 Sales Growing As CBD Sales Slow
MDMA5 hours ago
Rick Doblin Explains MAPS’ New $70 Million Investment Fund With Vine Ventures